RxDoctor Payments Data

Lana Gafter, MD

Nephrology · Roseville, CANPI 1376529552

Payments from drug & device makers

$1,753in general payments, 2019–2025

Across 30 payments — averaging $58.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$375
  • Novartis$353
  • Fresenius USA Marketing, Inc.$257
  • Nxstage Medical, Inc.$230
  • Vifor Pharma, Inc.$175
  • Otsuka America Pharmaceutical, Inc.$111
  • plus $252 from 7 others

What the payments were for

  • Consulting fees$37521%
  • Speaking & faculty fees$22513%
  • Food & beverage$1,04960%
  • Education$1046%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,753 in reported general payments places this provider in the 55th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$297,104
Medicare patients
648
Services billed
2,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan12$213,407
XphozahTenapanor Hcl17$47,560
FarxigaDapagliflozin Propanediol30$34,944
JardianceEmpagliflozin43$29,313
LokelmaSodium Zirconium Cyclosilicate21$29,165
Lanthanum Carbonate32$27,521
Sevelamer Carbonate37$16,944
VeltassaPatiromer Calcium Sorbitex15$14,083
Hydralazine Hcl208$4,540
Calcitriol251$4,216
Cinacalcet Hcl19$3,735
Calcium Acetate26$2,635
Valsartan45$2,135
Olmesartan Medoxomil96$2,099
Terazosin Hcl40$2,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$111$213,40712 claims
AstraZenecaFarxiga, Lokelma$14$64,10951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,341 nephrology providers in California.

Other nephrology in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →